These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23439006)

  • 1. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.
    Pasero C; Olive D
    Immunol Lett; 2013 Mar; 151(1-2):71-5. PubMed ID: 23439006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
    Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review.
    Karakatsanis S; Bertsias G; Roussou P; Boumpas D
    Hematol Oncol; 2014 Sep; 32(3):113-9. PubMed ID: 24038528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
    Cheung TC
    Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
    Pasero C; Speiser DE; Derré L; Olive D
    Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA.
    Croft M
    Trends Immunol; 2005 Jun; 26(6):292-4. PubMed ID: 15922943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct characteristics of BTLA/HVEM axis expression on Tregs and its impact on the expansion and attributes of Tregs in patients with active pulmonary tuberculosis.
    Tang P; Shen X; Gao J; Zhang J; Feng Y; Zhang J; Huang Z; Wang X
    Front Cell Infect Microbiol; 2024; 14():1437207. PubMed ID: 39386167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.
    Pasero C; Truneh A; Olive D
    Curr Mol Med; 2009 Sep; 9(7):911-27. PubMed ID: 19860669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
    Murphy TL; Murphy KM
    Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
    del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
    J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
    Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
    Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BTLA and HVEM cross talk regulates inhibition and costimulation.
    Gavrieli M; Sedy J; Nelson CA; Murphy KM
    Adv Immunol; 2006; 92():157-85. PubMed ID: 17145304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.
    Dalle S; Verronese E; N'Kodia A; Bardin C; Rodriguez C; Andrieu T; Eberhardt A; Chemin G; Hasan U; Le-Bouar M; Caramel J; Amini-Adle M; Bendriss-Vermare N; Dubois B; Caux C; Ménétrier-Caux C
    Oncoimmunology; 2024; 13(1):2372118. PubMed ID: 38939518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
    Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
    J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
    Merelli B; Massi D; Cattaneo L; Mandalà M
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
    Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
    PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.